Wave Life Sciences (WVE) Non-Current Deffered Revenue (2016 - 2026)

Wave Life Sciences (WVE) has 11 years of Non-Current Deffered Revenue data on file, last reported at $13.9 million in Q2 2026.

• Quarterly Non-Current Deffered Revenue rose 228.54% year-over-year to $13.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.9 million (up 228.54% YoY) and the FY2025 annual result came in at $7.8 million, up 27.86% from the prior year.
• Non-Current Deffered Revenue retreated to $13.9 million in Q2 2026, from $14.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $130.8 million in Q1 2023 to a low of $4.2 million in Q2 2025.
• A 5-year average of $42.9 million and a median of $15.1 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue tumbled 90.83% — and 2026, when it surged 228.54%.
• Tracing WVE's Non-Current Deffered Revenue over 5 years: stood at $79.8 million in 2022, then sank by 80.44% to $15.6 million in 2023, then sank by 60.91% to $6.1 million in 2024, then grew by 27.86% to $7.8 million in 2025, then soared by 78.3% to $13.9 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $13.9 million (Q2 2026), $14.6 million (Q1 2026), and $7.8 million (Q4 2025), per Business Quant data.